

16-17 OCT

Hôtel le Saint Paul  
Nice, France

16 NOV

Online

11<sup>th</sup>

**HEART FAILURE**  
**G U I D E L I N E S**  
**FOR U M**  
**2023**

*PROGRAM*

**October 16<sup>th</sup>**  
**12:30-19:30 CEST**

11<sup>th</sup>  
**HEART FAILURE**  
**GUIDELINES**  
**FOR U M**  
**2023**

**12:30 Lunch**

**13:30–13:35 Welcome / Introductions**

*S Anker, J Butler*

**13:35–14:10 Session 1 – New aspects in Heart Failure Guidelines methodologies**

*Session chairs: S Anker, A Coats*

- ESC guideline update: production & highlights – *M Metra*
- Conflict of interest rules – *G Rosano (Europe) & P Heidenreich (USA)*
- International Guideline “time-tables” – *S Zieroth*
- Class I recommendations for PRO outcomes?! – *B Bozkurt*

*General Discussion*

**14:10–15:00 Session 2 – Drugs vs Devices or Drugs and Devices**

*Session chairs: S Anker, S Zieroth*

- Are HF-GLs too drug centred? – *I Piña*
- Are there enough device treatment referral statements in the GLs? – *PC Schulze*
- What can current HF GLs learn from other (interventional therapy focussed) GLs on this? – *S von Bardeleben*
- Does GDMT obviate the need for ICD to prevent sudden cardiac death – *G. Hindricks*
- The regulator’s views – *FDA / EMA*

*General Discussion*

**15:00-15:15 Break**

**15:15–15:55 Session 3 – What about enablement scenarios**

*Session chairs: M Metra, S Zieroth*

- Hyperkalemia & potassium binders – *G Savarese*
- Hyperkalemia & SGLT2-inhibitors – *J Butler*
- Single-pill combinations – *G Rosano*

*General Discussion*

**15:55–16:55 Session 4 – Sorting out comorbidities & special problems (part 1)**

*Session chairs: S Anker, J Butler*

**Weight management for obesity**

- Short review of STEP-HFpEF – *M Kosiborod*
- Is Semaglutide an HFpEF therapy or a comorbidity therapy in the GLs? – *M Petrie*

*General Discussion*

**All about the WinRatio**

- How to recommend in GLs based on WinRatio benefits? – *A Coats*
  - The regulator’s views – *FDA / EMA*
- General Discussion*

**16:55–17:20 Session 5 – Sorting out comorbidities & special problems (part 2) –**

*Session chairs: W Abraham, A Coats*

- Resistant hypertension: Some basic facts on forgotten entity – *M Böhm*
- For HFpEF we now also have a class I recommendations to treat by aetiology: should HCM and Amyloidosis diagnosis get more attention in HF GLs? – *W Haverkamp*

*General Discussion*

**17:20-17:30 Break**

**17:30-18:10 Session 6 – HF Diagnosis & HF classification**

*Session chairs: J Butler, M Metra*

- LVEF is here to stay to classify HF? – *S Solomon*
  - What about HF<sub>n</sub>EF instead of HFpEF? – *J Cleland*
  - What about HF<sub>imp</sub>EF? – *J McMurray*
- General Discussion*

**18:10–19:10 Session 7 – Sorting out comorbidities & special problems (part 3)**

**Iron deficiency**

*Session chairs: J Butler, A Coats*

- The rationale for the updated IV-iron recommendation – *M Metra*
  - IV-iron: new meta-analyses – *P Ponikowski*
  - Problems and opportunities – *M Packer*
  - ID diagnosis – *J Cleland*
  - IV-iron: stopping rules for therapy – *S Anker*
- General Discussion – 1<sup>st</sup> discussant R Mentz*

**19:10–19:30 Ad hoc Q & A session (part 1) –**

*Session chairs: W Abraham, J Butler*

**October 17<sup>th</sup>**  
**08:15-14:30 CEST**

11<sup>th</sup>  
**HEART FAILURE**  
**GUIDELINES**  
**FOR URM**  
**2023**

**08:15 Welcome**

**08:15–08:45 Session 8 – Cancer session**

*Session chairs: A Coats, S Zieroth*

- Prevention of cardio-toxicity in cancer – *S. von Haehling*
- HF in advanced cancer using innovative biomarkers for assessment – *M Anker*

*General discussion*

**08:45–09:30 Session 9 – SGLT2 inhibitors**

*Session chairs: S Anker, A Coats*

- 1A for only 2 SGLT2-inhibitors in HF?! – *M Metra*
- HF with improved EF – *J Ezekowitz*
- Prevention of HF post AMI: one win means “everybody” wins?! If so, who is “everybody”? – *J Butler*
- What about sotaglifozin in non-diabetic patients? – *M Metra*
- The regulator’s views – *FDA / EMA*

*General discussion*

**09:30–10:00 Session 10 – What about prevention statements in the GLs?!**

*Session chairs: S Anker, S Zieroth*

- Prevention of HF vs prevention of HF hospitalisation – *M Metra*
- In CKD patients (SGLT2i & Finerenone)? In T2DM? – *G Filippatos*
- In post-AMI patients? – *J Butler*

*General discussion*

**10:00-10:40 Session 11 – Acute, advanced and worsening heart failure**

*Session chairs: W Abraham, S Zieroth*

- Is vericiguat a 5th pillar:
  - Yes, for all HF? – *J Butler*
  - Yes, but only if one of the other pillar therapies failed? – *G Filippatos*
  - Yes, but only in advanced / worsening HF? – *O Chioncel*
- Omecamtiv Mecarbil: Possible positioning in GLs if EMA approved? – *J Teerlink*

*General discussion*

**10:40-10:55 Break**

**10:55-11:35 Session 12 – Targeting valvular disease**  
*Session chairs: S Anker, A Coats*

**Functional MR**

- MitraClip – *S von Bardeleben*
- Carillon – *K Witte*

*General discussion*

**TR**

- State of trial affairs (completed & ongoing) – *S von Bardeleben*
- Relevance of valvular heart disease trials for HF GLs when the trials did not call it an HF trial – *S von Bardeleben*

*General discussion*

**11:35–12:15 Session 13 – Remote care approaches**

*Session chairs: S Anker, A Coats*

- GLs recommend strongly congestion assessment in WHF: What does it take to recommend that this is done objectively with a device-based approach like ReDS?! – *W Abraham*
- HF Hospitalization: how to identify high-risk patient – *F Ahmed*
- Cardiomems for remote monitoring – *W Abraham*

*General discussion*

**12:15-12:50 Session 14 – HFrEF treatment algorithms & personalised approaches**

*Session chairs: J Butler, S Zieroth*

- ARNI – not yet 1A (in Europe)?! – *M Metra*
- Strong-HF – how applicable in the real world? – *A Mebazaa*
- Achieving timely CRT for Heart Failure: should our guidelines be improved? – *L Lund*

*General discussion*

**12:50-13:20 Lunch Break**

**13:20-14:00 Session 15 – Additional device based solutions to prevent and treat HF**

*Session chairs: J Butler, S Zieroth*

- SuperSaturated Oxygen therapy post MI to prevent HF – *S Anker*
- Intra-atrial shunts?! – *W Abraham*

*General discussion*

**14:00–14:30 Ad hoc Q & A session (part 2)**

*Session chairs: S Anker, J Butler*

**Conclusion** – *S Anker*

**November 16<sup>th</sup>**  
**15:30 – 18:30 CET**

11<sup>th</sup>  
**HEART FAILURE**  
**GUIDELINES**  
**FORUM**  
2023

**15:30-15:35 Welcome and summary of past discussions**

**15:30-17:00 New trial results**

- *ARIES HM3*
- *ANTHEM-HFrEF*
- *STEP-HFrEF Trial*
- *ATTRIBUTE-CM*
- *GUIDE-HF*

**17:00-17:15 Break**

**17:15-17:35 Revisiting possible treatment algorithms after the AHA (part 1)**

**17:35-17:50 Revisiting possible treatment algorithms after the AHA (part 2)**

**17:50-18:20 Ad hoc Q & A session**

**18:20 -18:30 Conclusion**

## Chairs



William T. Abraham



Stefan Anker



Javed Butler



Marco Metra



Shelley Zieroth

## Faculty

### Europe

- Fozia Ahmed
- Angeles Alonso-Garcia
- Markus Anker
- Michael Böhm
- Ovidiu Chioncel
- John G.F. Cleland
- Andrew Coats
- Gerasimos Filippatos
- Evangelos Giannitsis
- Wilhelm Haverkamp
- Gerhard Hindricks
- Mitja Lainscak
- Lars Lund
- John McMurray
- Alexandre Mebazaa
- Mark Petrie

- Piotr Ponikowski
- Giuseppe Rosano
- Gianluigi Savarese
- Petar M. Seferovic
- Christian Schulze
- Stephan von Bardeleben
- Stephan von Haehling
- Adriaan A. Voors (16-Nov)
- Klaus Witte

### USA / Canada

- Biykem Bozkurt
- Justin Ezekowitz
- Paul A. Heidenreich
- Mikhail Kosiborod
- Robert J. Mentz

- Milton Packer
- Ileana Piña
- Scott Solomon
- John Teerlink

### Asia

- Vijay Chopra
- Jian Zhang
- Yuhui Zhang

### EMA

- John-Joseph Borg

### FDA

- Jordan Pomeroy
- Mary Ross Southworth
- Bram Zuckerman

## Practical details

### WHERE?

**Hotel le Saint Paul**  
29 boulevard Franck Pilatte  
Nice, France  
<https://lesaintpaul-hotel.fr/>

The hotel is located at 20 minutes from the Nice Airport.

## Contact us

### ORGANISATION

- **Frank Koall - Managing Director**  
Tel +41 (0)79 664 29 63  
Email: [frank.koall@tmacademy.org](mailto:frank.koall@tmacademy.org)
- **Charles Schoen - Operations Director**  
Tel.: +33 (0) 6 08 18 77 08  
Email:  
[charles.schoen@tmacademy.org](mailto:charles.schoen@tmacademy.org)

### SPONSORSHIP

- **Fabrice Poller**  
Tel: +33 (0) 6 99 66 19 73  
Email: [fpoller@tmacademy.org](mailto:fpoller@tmacademy.org)

More information on <https://www.tmacademy.org>

